Not available

General Information


DRACP ID  DRACP01824

Peptide Name   Not available

Sequence  YRPWGSGSGF

Sequence Length  10

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetics

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MeW155 Human melanoma Carcinoma Peptide at 0.004 mM decreased the number of tumour cells to 65% of the control, a 0.02 mMol concentration decreased the number of cells to 49%, and a concentration of 0.1 mM was toxic to melanoma cell Cell proliferation assay Not available Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01824

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C52H68N14O14

Absent amino acids  ACDEHIKLMNQTV

Common amino acids  G

Mass  127389

Pl  9.35

Basic residues  1

Acidic residues  0

Hydrophobic residues  2

Net charge  1

Boman Index  -1373

Hydrophobicity  -83

Aliphatic Index  0

Half Life 
  Mammalian: 2.8 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  6990

Absorbance 280nm  776.67

Polar residues  6

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID WO2009/015602A1

Patent Title  Polypeptides Having Anticancer Activity

Other Iinformation  Patent Application; Family: 10s / 10ex; Family Jurisdictions: WO, CN, EP, JP, US; Legal Status: Pending; Application No: 2008071804; Filed: Jul 30, 2008; Published: Feb 5, 2009; Earliest Priority: Jul 31, 2007

Other Published ID  CN100590130C  CN101168563A  EP2184295A1  EP2184295A4  EP2184295B1  JP2010534689A  JP5707594B2  US2010145012A1  US8207122B2 




DRACP is developed by Dr.Zheng's team.